Postoperative Pain Management after Hip Replacement
Conditions
Interventions
Control (Sufentanil) Group: Patients received Patient-Controlled Intravenous Analgesia (PCIA) : Sufentanil at a dose of 2.5 µg/kg.
Low-Dose Nalbuphine Arm: PCIA protocol.:Nalbuphine 0.5 mg/kg + Sufentanil 1.25 µg/kg
Moderate-Dose Nalbuphine Arm: PCIA protocol.:Nalbuphine 1.0 mg/kg + Sufentanil 1.25 µg/kg
High-Dose Nalbuphine Arm: PCIA protocol.:Nalbuphine 1.5 mg/kg + Sufentanil 1.25 µg/kg
Sponsors
Qingdao Huangdao District People‘s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1. Aged 18-80 years; 2. Scheduled for elective primary total hip arthroplasty (THA); 3. Signed informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1. Patients with psychiatric disorders; 2. Severe hepatic or renal impairment (e.g., eGFR <30 mL/min/1.73 m²); 3. Patients with hypersensitivity to opioids (nabumetone or morphine); 4. Patients with a history of long-term opioid use or substance abuse; 5. Patients unable to cooperate with pain assessment (e.g., due to cognitive impairment or language barriers)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resting VAS scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| SpO2;Time to first ambulation;Length of hospital stay (LOS);Total consumption of patient-controlled intravenous analgesia (PCIA);Patient satisfaction;Resting VAS scores; | — |
Countries
China
Contacts
Public ContactQing Liu
Qingdao Huangdao District People‘s Hospital
Outcome results
None listed